Skip to main content

Advertisement

SpringerLink
Log in

Mild renal dysfunction defined by creatinine clearance rate has limited impact on clinical outcomes after allogeneic hematopoietic stem cell transplantation

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Creatinine clearance rate (Ccr) is a more accurate indicator of renal function than serum creatinine. Data are sparse regarding the prognostic value of renal impairment calculated using Ccr in patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT). We performed a retrospective analysis of 185 patients who underwent allo-HSCT. These patients were divided into two groups by Ccr (ml/min) before transplantation; one showed normal renal function (Ccr ≥ 60, n = 156) and the other showed mild renal dysfunction (30 ≤ Ccr < 60, n = 29), and transplant outcomes were compared between the groups. We observed no significant difference between the groups in terms of clinical characteristics other than age, estimated glomerular filtration rate, serum creatinine, Ccr predicted by Cockcroft–Gault formula, primary disease, and conditioning intensity. With respect to transplant outcomes, no significant difference was observed in overall survival, relapse, or non-relapse mortality between the two groups. Multivariate analysis demonstrated that 30 ≤ Ccr < 60 before allo-HSCT was not an independent prognostic factor for transplant outcome. In conclusion, these results suggest that patients with mild renal dysfunction, defined as 30 ≤ Ccr < 60 ml/min, can safely undergo allo-HSCT. However, a larger series of patients is needed to evaluate the impact of mild renal dysfunction before allo-HSCT in more detail.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Yanada M. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective. Int J Hematol. 2015;101:243–54.

    Article  CAS  PubMed  Google Scholar 

  2. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Heher EC, Spitzer TR. Hematopoietic stem cell transplantation in patients with chronic kidney disease. Semin Nephrol. 2010;30:602–14.

    Article  PubMed  Google Scholar 

  4. Sorror ML, Giralt S, Sandmaier BM, De Lima M, Shahjahan M, Maloney DG, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110:4606–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Swedko PJ, Clark HD, Paramsothy K, Akbari A. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med. 2003;163:356–60.

    Article  CAS  PubMed  Google Scholar 

  6. Inoue N, Watanabe H, Okamura K, Kondo S, Kagami S. Are the equations for the creatinine-based estimated glomerular filtration rate applicable to the evaluation of renal function in Japanese children and adult patients receiving chemotherapy? Clin Exp Nephrol. 2015;19:298–308.

    Article  CAS  PubMed  Google Scholar 

  7. Oshima K, Kanda Y, Nanya Y, Tanaka M, Nakaseko C, Yano S, et al. Allogeneic hematopoietic stem cell transplantation for patients with mildly reduced renal function as defined based on creatinine clearance before transplantation. Ann Hematol. 2013;92:255–60.

    Article  CAS  PubMed  Google Scholar 

  8. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.

    CAS  PubMed  Google Scholar 

  9. Shingai N, Morito T, Najima Y, Kobayashi T, Doki N, Kakihana K, et al. Early-onset acute kidney injury is a poor prognostic sign for allogeneic SCT recipients. Bone Marrow Transplant. 2015;50:1557–62.

    Article  CAS  PubMed  Google Scholar 

  10. Kersting S, Verdonck LF. Successful outcome after nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with renal dysfunction. Biol Blood Marrow Transplant. 2008;14:1312–6.

    Article  PubMed  Google Scholar 

  11. de Souza JA, Saliba RM, Patah P, Rondon G, Ribeiro R, de Padua Silva L, et al. Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:1094–9.

    Article  PubMed  Google Scholar 

  12. Ikegame K, Yoshida T, Yoshihara S, Daimon T, Shimizu H, Maeda Y, et al. Unmanipulated haploidentical reduced-intensity stem cell transplantation using fludarabine, busulfan, low-dose antithymocyte globulin, and steroids for patients in non-complete remission or at high risk of relapse: a prospective multicenter phase I/II study in Japan. Biol Blood Marrow Transplant. 2015;21:1495–505.

    Article  CAS  PubMed  Google Scholar 

  13. Bodge MN, Reddy S, Thompson MS, Savani BN. Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic kidney disease: analysis of the literature and recommendations. Biol Blood Marrow Transplant. 2014;20:908–19.

    Article  PubMed  Google Scholar 

  14. Terakura S, Wake A, Inamoto Y, Murata M, Sakai R, Yamaguchi T, et al. Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil. Bone Marrow Transplant. 2017;52:423–30.

    Article  CAS  PubMed  Google Scholar 

  15. Lee JH, Joo YD, Kim H, Ryoo HM, Kim MK, Lee GW, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol. 2013;31:701–9.

    Article  CAS  PubMed  Google Scholar 

  16. Jo T, Arai Y, Kondo T, Kitano T, Hishizawa M, Yamashita K, et al. Chronic kidney disease in long-term survivors after allogeneic hematopoietic stem cell transplantation: retrospective analysis at a single institute. Biol Blood Marrow Transplant. 2017;23:2159–65.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We are very grateful to the patients in the current study. The authors would like to thank the nursing staff at our institution.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikatacho, Kita-ku, Okayama, Okayama, 700-0914, Japan

    Shuntaro Ikegawa, Ken-ichi Matsuoka, Tomoko Inomata, Naoto Ikeda, Hiroyuki Sugiura, Taiga Kuroi, Takeru Asano, Shohei Yoshida, Hisakazu Nishimori, Nobuharu Fujii, Eisei Kondo, Yoshinobu Maeda & Mitsune Tanimoto

Authors
  1. Shuntaro Ikegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ken-ichi Matsuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomoko Inomata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naoto Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroyuki Sugiura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Taiga Kuroi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takeru Asano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shohei Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hisakazu Nishimori
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nobuharu Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Eisei Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yoshinobu Maeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Mitsune Tanimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ken-ichi Matsuoka.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ikegawa, S., Matsuoka, Ki., Inomata, T. et al. Mild renal dysfunction defined by creatinine clearance rate has limited impact on clinical outcomes after allogeneic hematopoietic stem cell transplantation. Int J Hematol 107, 568–577 (2018). https://doi.org/10.1007/s12185-017-2398-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-017-2398-7

Keywords

Search

Navigation